Form 4: REGENXBIO Director Jennifer Zachary Receives Equity Grant

Director Jennifer Zachary was granted 9,807 restricted stock units and 46,600 stock options by REGENXBIO Inc.

Summary

• Director Jennifer Zachary received an equity grant consisting of 9,807 restricted stock units (RSUs) and 46,600 stock options.
• The RSUs and stock options are scheduled to vest on May 29, 2027, contingent upon continuous service to the company.
• The stock options have an exercise price of $7.01 per share and an expiration date of May 29, 2036.
• Following this transaction, the director's total beneficial ownership of common stock increased to 31,871 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.
• Retention of key leadership through time-based vesting schedules.

Negatives

• Potential for future shareholder dilution upon the exercise of stock options and vesting of RSUs.

Risks

• Dependence on the director's continuous service for the vesting of equity awards.
• Market price volatility affecting the value of the granted equity.

Future Outlook

The filing does not provide forward-looking financial guidance, focusing solely on director equity compensation.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard practice in the biotechnology sector to ensure long-term alignment between board members and shareholders, particularly for companies in the clinical development stage.

Comparison to Industry Standards

• The use of time-based vesting for director equity is consistent with standard corporate governance practices in the U.S. biotech industry.
• The grant size is typical for non-employee director compensation packages in mid-cap pharmaceutical companies.

Stakeholder Impact

• Shareholders may experience minor dilution upon the eventual exercise of these options.

Next Steps

• Vesting of equity awards on May 29, 2027.

Key Dates

Keywords

REGENXBIO, RGNX, Form 4, Insider Trading, Equity Compensation, Director Compensation, Biotech